Are research peptides safe?

The published record is too thin to support an answer in either direction. Neither BPC-157 nor TB-500 has completed a Phase III trial, and adverse-event information in circulation comes largely from animal studies, small trials and self-report rather than controlled clinical investigation.

What are the reported side effects of BPC-157?

The material in circulation most often describes mild gastrointestinal symptoms and local injection-site reactions where a parenteral route was used. That material derives from animal work, small trials and self-report, not from controlled clinical data, so it establishes neither incidence nor causation.

Does a Certificate of Analysis say anything about safety?

No. A COA establishes identity and purity — what is in the vial. It says nothing about what the substance does in a living system, and no analytical certificate has ever spoken to safety.

Why is BPC-157 on an FDA list?

It was placed in the FDA's Category 2 of bulk drug substances, meaning the agency identified significant safety risks for its use in compounding. That is a regulatory finding about the state of the evidence and is a matter of public record.

Is a peptide blend safer than the individual compounds?

There is less evidence behind a blend, never more. Each additional compound adds an interaction nobody has studied in a controlled human setting, so a three-component blend carries three components' worth of uncertainty plus the untested interactions between them.

Quality Control·5 min read

What the published safety record actually says

Reported adverse effects, and the much more important fact of how little controlled human data exists behind them. What is documented, what is self-reported, and what has never been studied.

The published safety record for most research peptides is thin. Neither BPC-157 nor TB-500 has completed a Phase III human trial, and for injectable BPC-157 no formal Phase I dose-escalation study appears in the literature. The adverse-event profiles in circulation are assembled from animal work, small trials and self-report.

By the Bench Grade Research Team · Last updated October 7, 2026

What is actually in the record

Safety information about these compounds is often presented as though it came from clinical trials. For most of them it did not. Distinguishing the sources is the single most useful thing a reader can do with this subject.

Where safety claims come from
Source type	What it can establish	What it cannot
Animal studies	Effects in that species at those parameters	Human safety, or effects at other parameters
Small human trials	Signals in a small sample	Rare events, or long-term outcomes
Self-reported community data	What people say happened	Causation, incidence, or anything about frequency
Phase III trials	Incidence against a control	— (largely absent here)

What is commonly reported

Across the material reported for BPC-157 and TB-500, the effects most often described in that literature are mild gastrointestinal symptoms — nausea, bloating, altered bowel habit — and local reactions at an injection site, including redness, swelling and transient pain where a parenteral route was used.

Systemic effects are described as uncommon in that material. That phrasing should be read carefully: uncommon in a body of self-report is not the same as uncommon in a population, because self-report captures neither the denominator nor the cases that stopped reporting.

The absence that matters most

No completed Phase III trial for either compound.
No published Phase I dose-escalation study for injectable BPC-157 with comprehensive safety monitoring.
No controlled human study of the two compounds administered together, so nothing is known about interaction in either direction.
No long-term outcome data, because the studies that would generate it have not been run.
For multi-component blends, each additional compound adds an untested interaction rather than additional evidence.

Why the FDA position matters here

BPC-157 was placed on the FDA's Category 2 list of bulk drug substances — substances for which the agency identified significant safety risks for use in compounding. That is a regulatory finding about the state of the evidence, and it is a matter of public record regardless of what any supplier says about purity or manufacturing.

A compound can be well-made and still be poorly characterised. Purity describes what is in the vial. It says nothing about what the substance does, and no Certificate of Analysis has ever spoken to safety.

How to read a supplier's safety claims

"Well tolerated in studies" — ask which studies, in which species, at what parameters, and over how long.
"No known side effects" — an absence of knowledge, presented as a finding.
"Extensively researched" — check whether the research is human or animal, and whether any of it reached Phase III.
"Third-party tested" — true and relevant to identity and purity, irrelevant to safety.
Any specific incidence figure — ask for the denominator. Self-reported data does not have one.

What we do and do not claim

We publish per-lot third-party analysis establishing what is in the vial: identity, purity, and the analytical methods used. We make no claim about safety, efficacy or suitability for any use in humans or animals, because we have no basis on which to make one and neither does anyone else selling these compounds.

The studies indexed in the research library on this site are the primary sources. They are linked so that what was actually measured can be read directly rather than through a summary — including ours.

References

Primary literature for the compounds discussed above. Links open the record on PubMed.

The potential of GHK as an anti-aging peptide Pickart L, et al. Aging Pathobiol Ther. 2022. PMID 35083444 → · summary
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data Pickart L, et al. Int J Mol Sci. 2018. PMID 29986520 → · summary
BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing Sikiric P, et al. Curr Pharm Des. 2018. PMID 29998800 → · summary
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration Chang CH, et al. J Appl Physiol. 2011. PMID 21030672 → · summary
Thymosin beta 4 improves dermal burn wound healing via downregulation of receptor of advanced glycation end products in db/db mice Xu TJ, et al. Biochim Biophys Acta. 2014. PMID 25230158 → · summary
Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat Cerovecki T, et al. J Orthop Res. 2010. PMID 20225319 → · summary
Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat Novinscak T, et al. Surg Today. 2008. PMID 18668315 → · summary
Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation Krivic A, et al. J Orthop Res. 2006. PMID 16583442 → · summary

Primary sources

Frequently asked questions

Are research peptides safe?: The published record is too thin to support an answer in either direction. Neither BPC-157 nor TB-500 has completed a Phase III trial, and adverse-event information in circulation comes largely from animal studies, small trials and self-report rather than controlled clinical investigation.
What are the reported side effects of BPC-157?: The material in circulation most often describes mild gastrointestinal symptoms and local injection-site reactions where a parenteral route was used. That material derives from animal work, small trials and self-report, not from controlled clinical data, so it establishes neither incidence nor causation.
Does a Certificate of Analysis say anything about safety?: No. A COA establishes identity and purity — what is in the vial. It says nothing about what the substance does in a living system, and no analytical certificate has ever spoken to safety.
Why is BPC-157 on an FDA list?: It was placed in the FDA's Category 2 of bulk drug substances, meaning the agency identified significant safety risks for its use in compounding. That is a regulatory finding about the state of the evidence and is a matter of public record.
Is a peptide blend safer than the individual compounds?: There is less evidence behind a blend, never more. Each additional compound adds an interaction nobody has studied in a controlled human setting, so a three-component blend carries three components' worth of uncertainty plus the untested interactions between them.

Compounds discussed in this guide

Who publishes this guide

Who sells it: Bench Grade Peptides LLC, a US supplier of lyophilized synthetic peptides for laboratory research use only. It works with US manufacturing partners rather than running a facility of its own. Is Bench Grade Peptides legit? →
Certificates of Analysis: 139 third-party Certificates of Analysis covering 39 of 44 live products, published per lot in a public library anyone can read before ordering. A very recent lot can appear a few days after it enters the catalogue. COA library →
Ships from: Florida, by UPS, to US addresses only (no international shipping). The registered address in Dover, Delaware is the legal address only. Shipping →
Use: For laboratory research use only — not for human or veterinary use. Not a drug, supplement or medical device. Compliance and research use →

All products discussed in this guide are supplied by Bench Grade Peptides for laboratory research use only. Not for human or veterinary use.